(Q41329947)

English

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 September 2017

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five- (English)

1 reference

Europe PubMed Central

29 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

E Claire Dees

1 reference

Europe PubMed Central

29 September 2017

author name string

Bohuslav Melichar

1

1 reference

Europe PubMed Central

29 September 2017

Antoine Adenis

2

1 reference

Europe PubMed Central

29 September 2017

A Craig Lockhart

3

1 reference

Europe PubMed Central

29 September 2017

Jaafar Bennouna

4

1 reference

Europe PubMed Central

29 September 2017

Omar Kayaleh

6

1 reference

Europe PubMed Central

29 September 2017

Radka Obermannova

7

1 reference

Europe PubMed Central

29 September 2017

Angela DeMichele

8

1 reference

Europe PubMed Central

29 September 2017

Petr Zatloukal

9

1 reference

Europe PubMed Central

29 September 2017

Bin Zhang

10

1 reference

Europe PubMed Central

29 September 2017

Claudio Dansky Ullmann

11

1 reference

Europe PubMed Central

29 September 2017

Claudia Schusterbauer

12

1 reference

Europe PubMed Central

29 September 2017

publication date

27 February 2015

1 reference

Europe PubMed Central

29 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

29 September 2017

16

1 reference

Europe PubMed Central

29 September 2017

4

1 reference

Europe PubMed Central

29 September 2017

395-405

1 reference

Europe PubMed Central

29 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Aurora A kinase (AURKA) in normal and pathological cell division

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Aurora kinases in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HDM2 regulation by AURKA promotes cell survival in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Managing patients with advanced and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic breast cancer: second line and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Small-cell lung cancer: an update on targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Aurora kinase inhibition as an anticancer strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity patterns of cytotoxic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970051-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70051-3

1 reference

Europe PubMed Central

29 September 2017

1 reference

Europe PubMed Central

29 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41329947&oldid=2095906526"